Le linee ricerca attivate dal network di pazienti-esperti-per-i-pazientiISOPROG-Somatolink riguardano:

A. I meccanismi molecolari utilizzati da fattori secreti dalle cellule tumorali, i cui risultati hanno generato i seguenti lavori scientifici:

  1. Scalia P, Pandini G, Carnevale V, Giordano A, Williams SJ. Identification of a Novel EphB4 Phosphodegron Regulated by the Autocrine IGFII/IRA Axis in Malignant Mesothelioma. Oncogene, 38:5987-6001,2019. doi: 10.1038/s41388-019-0854-y
  2. Scalia P, Williams SJ, Giordano A. Core elements cloning, cis-elements mapping and serum regulation of the Human EphB4 Promoter: A Novel TATA-Less Inr/MTE/DPE-like Regulated Gene. Genes,10, 997, 2019. doi:10.3390/genes1012099
  3. Scalia, P.; Giordano, A.; Williams, S.J. The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives (review). Cancers, 12(2), 366, 2020. Doi: 10.3390/cancers12020366
  4. Scalia, P.; Heart, E.; Doughty, A; Giordano, A; Williams, S.J. Vitronectin Negatively Regulates IGF-II-Induced Mitogenic Signaling and Migration Mediated By The Insulin Receptor Isoform-A. Int J Appl Biol Pharm, 11(3), 229-244, 2020 
  5. Scalia, P., Giordano, A., Martini, C., Williams, S.J. Isoform-and paralog-switching in IR-signaling: When diabetes opens the gates to cancer. Biomolecules, 2020, 10(12), pp. 1–17, 1617 
  6. Scalia, P., Maurancy, J., Giordano, A., Williams, S.J. Transcriptional and Post-Translational Control Mechanisms for EphB4 Expression in Physiology and Cancer Disease. 2021, 31(2), pp. 83–88

B. La ottimizzazione dei processi di Biobanking e della profilazione “omica” guidata da intelligenza artificiale in oncologia e patologia umana, I cui risultati hanno originato le seguenti pubblicazioni:

  1. Scalia P and Williams SJ. An Expert Patients-for-Patients integrated Biobanking-CRO Operational Model For Sustainable Personalized Oncology. Biomedical Journal of Science and Technological Research, 2020 Published on March 11th; Doi 10.26717/BJSTR.2020.26.004367
  2. Scalia P (panel speaker). Actionable Molecular Oncology Targets in Tissue High Content Screening Platform: Moving Proteomics Profiling to the Patient Bed. Tissue Microarray Workshop in Quantitative Digital Proteomics in Pathology. Philadelphia, USA, Children Hospital of Philadelphia, University of Pennsylvania, Buerger Center, November 17, 2017
  3. Scalia P (Panel speaker). Combined use of Laser Capture Microdissection and Geno-transcriptomic Analysis for cancer fingerprinting. Convention on “The Evolution of Molecular Biology in Anatomic Pathology”, Palermo, Italy, Hospital ARNAS Civico, June 24th, 2015
  4. Scalia P (panel speaker). Biobanking of Solid Tumors for Research & in Predictive-Preventive Screening: Limits & Perspectives. Convention of the Regional Oncologic Network, Sicily, CEFPAS Campus, Caltanissetta, Italy, April 10th, 2015
  5. Scalia P and Lo Presti G. Synergistic Data Integration in the Age of Personalized Medicine. ESBB-LIMS Workshop, Milano, Italy, March 13-14, 2014.

C. La ottimizzazione di pannelli NGS per il fingerprinting delle cellule tumorali derivate dal paziente mirate a studi di personalizzazione dei trattamenti, il cui lavoro ha generato I seguenti risultati:

  1. Scalia P, Williams SJ, Russo A, Giordano A. 2017. Actionable Molecular Targets in Cancer Liquid Biopsy (Chapter in Book), p 71-76. Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution. Ed. Russo, Giordano & Rolfo. Humana Press, 2017
  2. Scalia P (panelist speaker). Oncogenomics and signaling pathways in the clonal evolution induced by drug- resistance in melanoma. 1stMediterranean congress on New Therapies in the Treatment of Melanoma. Palermo, Italy, Palazzo Steri, September 11th & 12th,2015
  3. Scalia, P; Williams, SJ; Ventura, E; Stanganelli, I; Giordano, A; Ferrau’, F; Asero, S. The Onco-genomic Landscape of Malignant Melanoma: The Tumor Microenvironment Comes Of Age. J Cancer Res Oncobiol Aug;3(3):130, 2020; doi 10.31021/JCRO.20203130